Opicinumab

Optic Neuritis RENEW Trial Results

Optic Neuritis RENEW Trial Results

By

The human monoclonal antibody opicinumab may potentially enhance spontaneous remyelination after acute optic neuritis.

Sign Up for Free e-Newsletters